Evidence map›Paper›PMID 36681177›Full record

ArticleMicrobes and infection2023

Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.

Isabel Hodl, Clarissa Sallegger, Patrick Forstner, Nazanin Sareban, Martina Moritz, Barbara Dreo, Eduard Schulz, Angelika Lackner, Barbara Kleinhappl, Stefan Hatzl and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbes and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Isabel HodlDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Clarissa SalleggerDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Patrick ForstnerInstitute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria.
Nazanin SarebanDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Martina MoritzDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Barbara DreoDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Eduard SchulzDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Angelika LacknerDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Barbara KleinhapplInstitute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria.
Stefan HatzlDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Florentine Moazedi-FürstDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Thomas Seifert-HeldDepartment of Neurology, Medical University of Graz, Graz, Austria.
Bettina HeschlDepartment of Neurology, Medical University of Graz, Graz, Austria.
Michael KhalilDepartment of Neurology, Medical University of Graz, Graz, Austria.
Christian EnzingerDepartment of Neurology, Medical University of Graz, Graz, Austria.
Hildegard GreinixDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Martin H StradnerDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Electronic address: martin.stradner@medunigraz.at.
Ivo SteinmetzInstitute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria.
Peter SchlenkeDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Johannes FesslerDivision of Immunology, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell depleting therapies result in diminished humoral immunity following vaccination against COVID-19, but our understanding on the impact on cellular immune responses is limited. Here, we performed a detailed analysis of cellular immunity following mRNA vaccination in patients receiving B-cell depleting therapy using ELISpot assay and flow cytometry. Anti-SARS-CoV-2 spike receptor-binding domain antibody assays were performed to elucidate B-cell responses. To complement our cellular analysis, we performed immunophenotyping for T- and B-cell subsets. We show that SARS-CoV-2 vaccination using mRNA vaccines elicits cellular T-cell responses in patients under B-cell depleting therapy. Some facets of this immune response including TNFα production of CD4

Indexed as

AutoimmunityCOVID-19Antibodies, ViralCD8-Positive T-LymphocytesCOVID-19 VaccinesHumansImmunity, CellularSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesAutoimmunityCovid-19OcrelizumabRituximabT-cellsVaccination

Identifiers

PMID36681177
PMCPMC9850844
OpenAlexW4317470415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.